LobbyingAmerican College of Cardiology lobbying by quarter
American College of Cardiology's latest lobbying report covers Q2 2026, at $680K. The four quarters Q4 2025–Q3 2026 total $1.8M. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
American College of Cardiology
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $1.8M
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $400K | 1 |
| Q1 2023 | $490K | 1 |
| Q2 2023 | $440K | 1 |
| Q3 2023 | $520K | 1 |
| Q4 2023 | $440K | 1 |
| Q1 2024 | $530K | 1 |
| Q2 2024 | $440K | 1 |
| Q3 2024 | $410K | 1 |
| Q4 2024 | $490K | 1 |
| Q1 2025 | $580K | 1 |
| Q2 2025 | $500K | 1 |
| Q3 2025 | $580K | 1 |
| Q4 2025 | $480K | 1 |
| Q1 2026 | $600K | 1 |
| Q2 2026 | $680K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$2.5M · 15 reports
- Medicare and Medicaid$2.5M · 15 reports
- Tobacco$2.5M · 15 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Agency for Healthcare Research & Quality (AHRQ)15 reports
- Centers For Disease Control & Prevention (CDC)15 reports
- Centers For Medicare and Medicaid Services (CMS)15 reports
- Food & Drug Administration (FDA)15 reports
- Health & Human Services, Dept of (HHS)15 reports
- HOUSE OF REPRESENTATIVES15 reports
- Medicare Payment Advisory Commission (MedPAC)15 reports
- Natl Institutes of Health (NIH)15 reports
- Office of Management & Budget (OMB)15 reports
- SENATE15 reports
- White House Office15 reports
- Commerce, Dept of (DOC)5 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseAmerican College of Cardiology | $7.6M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $680K |
| 04/20for Q1 | In-house | $600K |
| 01/20for Q4 2025 | In-house | $480K |
| 25/10/14for Q3 2025 | In-house | $580K |
| 25/07/11for Q2 2025 | In-house | $500K |
| 25/04/18for Q1 2025 | In-house | $580K |
| 25/01/21for Q4 2024 | In-house | $490K |
| 24/10/21for Q3 2024 | In-house | $410K |
| 24/07/22for Q2 2024 | In-house | $440K |
| 24/04/22for Q1 2024 | In-house | $530K |
| 24/01/22for Q4 2023 | In-house | $440K |
| 23/10/20for Q3 2023 | In-house | $520K |
| 23/07/20for Q2 2023 | In-house | $440K |
| 23/04/20for Q1 2023 | In-house | $490K |
| 23/01/20for Q4 2022 | In-house | $400K |